| Approved inhibitors |
| Clavulanic acid |
Amoxicillin or ticarcillin |
Class A, some class D |
61, 62
|
| Tazobactam |
Piperacillin |
Class A, some class D |
63
|
| Sulbactam |
Ampicillin or cefoperazone |
Class A |
64, 65
|
| Avibactam |
Ceftazidime |
Class A, C, D |
66
|
| Relebactam |
Imipenem/cilastatin |
Class A, C |
67, 68
|
| Vaborbactam |
Meropenem |
Class A, C |
67
|
| Developmental inhibitors in clinical trials |
| Nacubactam |
Meropenem – phase I trial |
Class A, C |
69, 70
|
| Zidebactam |
Cefepime – phase III trial |
Class A, C |
71
|
| ETX2514 |
Sulbactam – phase II trial |
Class A, C and some D |
72
|
| ETX0282 |
Cefpodoxime – phase I trial |
Class A, C |
73
|
| LN-1-255 |
Ceftazidime – phase II trial |
Class A, D (non-carbapenemases) |
74
|
| Enmetazobactam |
Cefepime – phase III trial |
Class A |
75, 76
|
| Taniborbactam |
Cefepime – phase II trial |
Class A, B, C, D |
77
|
| VNRX-7145 |
Cefibutin – phase I trial |
Class A, C, D |
78
|
| LK-157 |
Cefuroxime – phase I trial |
Class A, C |
78
|
| BLI-489 |
Piperacillin – phase II trial |
Class A, C, D |
79
|
|
d-Captopril |
Meropenem – phase I trial |
Class B |
80
|